文献速递脑血管病

急性缺血性卒中血管内治疗前静脉替罗非班与阿替普酶的对比:DEVT与RESCUE BT试验的汇总分析

Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials.
PubMed 文献 · Stroke · 2024-02-16

本研究汇总DEVT与RESCUE BT两项随机试验数据,比较颅内大血管闭塞4.5小时内替罗非班+EVT与阿替普酶桥接EVT的疗效与安全性。主要终点90天功能独立率替罗非班组60.2% vs 阿替普酶组46.6%(校正OR 1.25,95%CI 0.60-2.63),症状性颅内出血与死亡率无显著差异。

要点

  • 替罗非班+EVT与阿替普酶桥接EVT在90天功能独立率上无显著差异(校正OR 1.25,95%CI 0.60-2.63)。
  • 症状性颅内出血替罗非班组6.8% vs 阿替普酶组9.2%(P=0.51),无显著差异。
  • 3个月死亡率替罗非班组17.8% vs 阿替普酶组19.4%(P=0.76),无显著差异。

核心结论

  • 在颅内大血管闭塞发病4.5小时内患者中,替罗非班+EVT与阿替普酶桥接EVT在疗效和安全性结局上相当。
  • 这些发现应被视为初步结果,需要在随机试验中确认。

研究设计与样本

  • 本研究为对2项多中心随机试验(DEVT试验2018年5月至2020年5月;RESCUE BT试验2018年10月至2021年10月)的事后汇总分析。
  • 纳入发病4.5小时内急性颅内大血管闭塞患者,分为替罗非班+EVT组与阿替普酶桥接EVT组。
  • 共纳入DEVT试验中118例阿替普酶治疗患者和RESCUE BT试验中98例替罗非班治疗患者(中位年龄70岁;男性115例[53.2%])。
  • 采用多因素logistic回归(校正基线收缩压、闭塞部位、发病至穿刺时间、麻醉方式及EVT首选方式)和倾向评分重叠权重分析。

主要发现

  • 90天功能独立(改良Rankin量表评分0-2分)率替罗非班组为60.2%,阿替普酶组为46.6%(校正OR 1.25,95%CI 0.60-2.63)。
  • 症状性颅内出血发生率替罗非班组6.8% vs 阿替普酶组9.2%(P=0.51),替罗非班未增加风险。
  • 3个月死亡率替罗非班组17.8% vs 阿替普酶组19.4%(P=0.76),替罗非班未增加风险。
  • 倾向评分重叠权重分析显示结局一致。

局限性

  • 原文结论指出这些发现应被视为初步结果,需要在随机试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present study aimed to evaluate the efficacy and safety of intravenous tirofiban versus alteplase before endovascular treatment (EVT) in acute ischemic stroke patients with intracranial large vessel occlusion. METHODS: This was a post hoc analysis using data from 2 multicenter, randomized trials: the DEVT trial (Direct Endovascular Treatment for Large Vessel Occlusion Stroke) from May 2018 to May 2020 and the RESCUE BT trial (Intravenous Tirofiban Before Endovascular Thrombectomy for Acute Ischemic Stroke) from October 2018 to October 2021. Patients with acute intracranial large vessel occlusion within 4.5 hours from last known well were dichotomized into 2 groups: tirofiban plus EVT versus alteplase bridging with EVT. The primary outcome was functional independence (modified Rankin Scale score of 0-2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage and 3-month mortality. Multivariable logistic regression (adjusting for baseline systolic blood pressure, occlusion site, onset-to-puncture time, anesthesia, and first choice of EVT) and propensity score overlap weighting (balance in demographic covariates, stroke characteristics, and initial management between groups) were performed. RESULTS: One-hundred and eighteen alteplase-treated patients in the DEVT trial and 98 tirofiban-treated patients in the RESCUE BT trial were included (median age, 70 years; 115 [53.2%] men). The rate of functional independence was 60.2% in the tirofiban group compared with 46.6% in the alteplase group (adjusted odds ratio, 1.25 [95% CI, 0.60-2.63]). Compared with alteplase, tirofiban was not associated with increased risk of symptomatic intracranial hemorrhage (6.8% versus 9.2%; P=0.51) and mortality (17.8% versus 19.4%; P=0.76). The propensity score overlap weighting analyses showed consistent outcomes. CONCLUSIONS: Among patients with intracranial large vessel occlusion within 4.5 hours of onset, tirofiban plus EVT was comparable to alteplase bridging with EVT regarding the efficacy and safety outcomes. These findings should be interpreted as preliminary and require confirmation in a randomized trial. REGISTRATION: URL: https://www.chictr.org.cn; Unique identifiers: ChiCTR-IOR-17013568 and ChiCTR-INR-17014167.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sang H, Cao Z, Du J, et al. Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials. Stroke. 2024. PMID: 38362756. doi:10.1161/STROKEAHA.123.044562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。